These study results were published in Acute Pain Medicine. Study patients reported data on pain (0 to 10-point scale), quality of life (0 to 100-point scale), and functional disability (0 to 60-point ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

HealthDay News — Many very preterm infants experience pain, according to a study published online Jan. 21 in Pain. Hillary Graham, from the Karolinska Institutet in Stockholm, and colleagues explored ...

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.

Painkillers are a necessary medication that helps people be relieved of their pain whether it is temporary, or if it is ...

Further, we have shown that the instrument correlates well with results of other measures of pain and functional status. Accordingly, mean change in AOM-SOS scores from baseline to follow-up could ...

It works by switching off nociceptors in the peripheral nervous system, and therefore preventing pain signals getting to the ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...